5-Fluorouracil (5FU) treatment does not influence invasion and metastasis in microsatellite unstable (MSI-H) colorectal cancer

International Journal of Colorectal Disease

Volumn 21, Issue 7, 2006, Pages 625-631

  Warusavitarne, Janindra ^a   Ramanathan, Palaniappan ^a   Kaufman, Anthony ^b   Robinson, Bruce G ^a   Schnitzler, Margaret ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

5 Fluorouracil (5FU); Chemotherapy; Colorectal cancer; Metastasis; Microsatellite instability (MSI H)

Indexed keywords

FLUOROURACIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CANCER SIZE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL VIABILITY; COLON CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; DRUG RESPONSE; EXPERIMENTAL NEOPLASM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER METASTASIS; METASTASIS INHIBITION; MICROSATELLITE INSTABILITY; MOUSE; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; SPLEEN CANCER; SPLEEN WEIGHT;

ANIMALS; CELL COUNT; CELL SURVIVAL; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; FLUOROURACIL; HCT116 CELLS; HUMANS; LUMINESCENT MEASUREMENTS; MICE; MICROSATELLITE INSTABILITY; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS;

EID: 33749019730     PISSN: 01791958     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00384-005-0071-8     Document Type: Article

References (29)

1. Gryfe R, Kim H, Hsieh ET et al (2000) Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 342 (2): 69-77
2. Boland C, Thibodeau S, Hamilton S et al (1998) A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58 (22): 5248-5257
3. Gryfe R, Gallinger S (2001) Microsatellite instability, mismatch repair deficiency, and colorectal cancer. Surgery 130 (1): 17-20
4. Kochhar R, Halling KC, McDonnell S et al (1997) Allelic imbalance and microsatellite instability in resected Duke's D colorectal cancer. Diagn Mol Pathol 6 (2): 78-84
5. Hemminki A, Mecklin JP, Jarvinen H et al (2000) Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology 119 (4): 921-928
6. Elsaleh H, Shannon B, Iacopetta B (2001) Microsatellite instability as a molecular marker for very good survival in colorectal cancer patients receiving adjuvant chemotherapy. Gastroenterology 120 (5): 1309-1310
7. Ribic CM, Sargent DJ, Moore MJ et al (2003) Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349 (3): 247-257
8. Carethers JM, Chauhan DP, Fink D et al (1999) Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 117 (1): 123-131
9. Meyers M, Wagner MW, Hwang HS et al (2001) Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res 61 (13): 5193-5201
10. Yang JL, Friedlander ML (2001) Effect of nifedipine in metastatic colon cancer with DNA mismatch repair gene defect. Lancet 357 (9270): 1767-1768
11. Fink D, Aebi S, Howell SB (1998) The role of DNA mismatch repair in drug resistance. Clin Cancer Res 4 (1): 1-6
12. Pocard M, Bras-Goncalves R, Hamelin R et al (2000) Response to 5-fluorouracil of orthotopically xenografted human colon cancers with a microsatellite instability: Influence of P53 status. Anticancer Res 20 (1A): 85-90
13. Barratt PL, Seymour MT, Stenning SP et al (2002) DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: A molecular study. Lancet 360 (9343): 1381-1391
14. Clarke PA, George ML, Easdale S et al (2003) Molecular pharmacology of cancer therapy in human colorectal cancer by gene expression profiling. Cancer Res 63 (20): 6855-6863
15. Gartel AL, Feliciano C, Tyner AL (2003) A new method for determining the status of p53 in tumor cell lines of different origin. Oncol Res 13 (6-10): 405-408
16. O'Connor PM, Jackman J, Bae I et al (1997) Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57 (19): 4285-4300
17. Benn DE, Robinson BG (1996) Peripheral blood mononuclear cells are a reliable internal standard for the flow cytometric DNA analysis of frozen malignant breast biopsies. Cytometry 26 (2): 161-165
18. Morikawa K, Walker S, Nakajima M et al (1988) Influence of organ environment on the growth, selection, and metastasis of human colon carcinoma cells in nude mice. Cancer Res 48 (23): 6863-6871
19. Yeatman TJ, Cher ML, Mao WG et al (1996) Identification of genetic alterations associated with the process of human experimental colon cancer liver metastasis in the nude mouse. Clin Exp Metastasis 14 (3): 246-252
20. Yao M, Kargman S, Lam EC et al (2003) Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. Cancer Res 63 (3): 586-592
21. Morikawa K, Walker S, Jessup J et al (1988) In vivo selection of highly metastatic cells from surgical specimens of different primary human colon carcinomas implanted into nude mice. Cancer Res 48 (7): 1943-1948
22. Cascinu S, Georgoulias V, Kerr D et al (2003) Colorectal cancer in the adjuvant setting: Perspectives on treatment and the role of prognostic factors. Ann Oncol 14 (Suppl 2): Ii25-ii29
23. Elsaleh H, Joseph D, Grieu F et al (2000) Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 355 (9217): 1745-1750
24. van Laar JA, Rustum YM, Ackland SP et al (1998) Comparison of 5-fluoro-2′-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer. Eur J Cancer 34 (3): 296-306
25. Longley DB, Harkin DP, Johnston PG (2003) 5-Fluorouracil: Mechanisms of action and clinical strategies. Nat Rev Cancer 3 (5): 330-338
26. Longley DB, Boyer J, Allen WL et al (2002) The role of thymidylate synthase induction in modulating p53-regulated gene expression in response to 5-fluorouracil and antifolates. Cancer Res 62 (9): 2644-2649
27. Bunz F, Hwang PM, Torrance C et al (1999) Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 104 (3): 263-269
28. Claij N, te Riele H (1999) Microsatellite instability in human cancer: A prognostic marker for chemotherapy? Exp Cell Res 246 (1): 1-10
29. Fink D, Nebel S, Norris PS et al (1998) The effect of different chemotherapeutic agents on the enrichment of DNA mismatch repair-deficient tumour cells. Br J Cancer 77 (5): 703-708